Allogene Therapeutics expands board to 11, appoints Elizabeth Barrett and Vicki Sato as directors

Allogene Therapeutics, Inc.

Board increased from 9 to 11; Barrett (Class I) and Dr. Sato (Class II) appointed effective July 30, 2021.
Barrett receives annual retainer of $40,000 and option grant with $850,000 grant date value vesting over 3 years.
Dr. Sato receives $40,000 retainer, option grant of $425,000 value (3-year vest), and RSU award of $425,000 value (3 annual installments).
Both directors enter indemnification agreements; equity grants accelerate on change of control.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Elizabeth Barrett

Class I director

ALLO · Allogene Therapeutics, Inc.

Effective: 2021-07-30
Filed: August 2, 2021, 7:59 PM ET

appointed Elizabeth Barrett as a Class I director of the Company to fill one of the newly created vacancies, effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Elizabeth Barrett was appointed as Class I director at Allogene Therapeutics, Inc..

Action: appointed
Role: Class I director

Exact text from the filing

appointed Elizabeth Barrett as a Class I director of the Company to fill one of the newly created vacancies, effective immediately

View on SEC.gov

Allogene Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001737287-21-000034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.